Bausch + Lomb (NYSE:BLCO) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

Bausch + Lomb (NYSE:BLCO) had its price objective raised by JPMorgan Chase & Co. from $16.00 to $22.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The firm presently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s price objective points to a potential upside of 7.97% from the company’s current price.

BLCO has been the topic of a number of other reports. Wells Fargo & Company increased their price objective on Bausch + Lomb from $18.00 to $19.00 and gave the company an “equal weight” rating in a research report on Thursday. UBS Group initiated coverage on Bausch + Lomb in a report on Thursday, July 30th. They set a “buy” rating and a $21.00 price objective for the company. Weiss Ratings upgraded shares of Bausch + Lomb from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, August 21st. Barclays upgraded shares of Bausch + Lomb to a “strong-buy” rating in a research report on Wednesday, October 7th. Finally, HC Wainwright reissued a “buy” rating and set a $21.00 price target on shares of Bausch + Lomb in a research note on Friday, August 28th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $20.62.

Bausch + Lomb Stock Performance

Shares of NYSE BLCO traded down $0.02 during trading hours on Thursday, reaching $20.38. The stock had a trading volume of 3,425,082 shares, compared to its average volume of 465,881. The business’s fifty day moving average is $17.24 and its two-hundred day moving average is $16.66. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.55 and a quick ratio of 1.02. The company has a market cap of $7.28 billion, a price-to-earnings ratio of -42.45, a PEG ratio of 0.55 and a beta of 0.56. Bausch + Lomb has a twelve month low of $14.44 and a twelve month high of $21.36.

Bausch + Lomb (NYSE:BLCO) last issued its earnings results on Wednesday, October 28th. The company reported $0.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.21 by $0.13. The business had revenue of $1.38 billion during the quarter, compared to analysts’ expectations of $1.37 billion. Bausch + Lomb had a positive return on equity of 4.14% and a negative net margin of 3.21%. Bausch + Lomb’s quarterly revenue was up 7.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.18 EPS. As a group, research analysts expect that Bausch + Lomb will post 0.81 EPS for the current year.

Insider Activity at Bausch + Lomb

In other Bausch + Lomb news, CAO Frederick Munsch sold 52,900 shares of the stock in a transaction on Monday, August 10th. The shares were sold at an average price of $16.78, for a total value of $887,662.00. Following the completion of the sale, the chief accounting officer owned 45,831 shares in the company, valued at $769,044.18. This trade represents a 53.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Eschenbach Andrew C. Von sold 12,500 shares of the firm’s stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $16.50, for a total transaction of $206,250.00. Following the completion of the sale, the director owned 69,792 shares of the company’s stock, valued at $1,151,568. This trade represents a 15.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 71,459 shares of company stock worth $1,194,370 in the last ninety days. Insiders own 1.45% of the company’s stock.

Hedge Funds Weigh In On Bausch + Lomb

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Roxbury Financial LLC acquired a new stake in Bausch + Lomb in the third quarter valued at approximately $33,000. Royal Bank of Canada increased its holdings in shares of Bausch + Lomb by 67.1% during the first quarter. Royal Bank of Canada now owns 3,657 shares of the company’s stock valued at $58,000 after acquiring an additional 1,468 shares in the last quarter. State of Wyoming raised its position in shares of Bausch + Lomb by 6.9% during the third quarter. State of Wyoming now owns 13,772 shares of the company’s stock worth $234,000 after purchasing an additional 887 shares during the period. Handelsbanken Fonder AB raised its position in shares of Bausch + Lomb by 5.3% during the second quarter. Handelsbanken Fonder AB now owns 22,000 shares of the company’s stock worth $364,000 after purchasing an additional 1,100 shares during the period. Finally, Squarepoint Ops LLC lifted its holdings in shares of Bausch + Lomb by 31.7% in the 2nd quarter. Squarepoint Ops LLC now owns 24,379 shares of the company’s stock worth $404,000 after purchasing an additional 5,861 shares in the last quarter. 11.07% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Bausch + Lomb

Here are the key news stories impacting Bausch + Lomb this week:

• Positive Sentiment: Q3 results exceeded expectations: Adjusted EPS was $0.34 versus the $0.21 consensus estimate and $0.18 a year earlier. Revenue increased approximately 7.3% year over year to about $1.38 billion, slightly ahead of the $1.37 billion estimate. Bausch + Lomb Surpasses Q3 Earnings and Revenue Estimates
• Positive Sentiment: 2026 outlook was raised: Bausch + Lomb now expects full-year revenue of $5.450 billion to $5.550 billion and adjusted EBITDA of $1.090 billion to $1.140 billion. Management cited continued momentum from its Vision ’27 strategy and strong growth across its eye-care businesses. Bausch + Lomb Raises 2026 Guidance
• Positive Sentiment: RBC became more bullish: RBC raised its price target to $23 from $21 while maintaining an Outperform rating, indicating greater confidence in the company’s earnings momentum and longer-term growth prospects. RBC Raises Price Target
• Neutral Sentiment: Analyst views remain mixed: Deutsche Bank raised its target to $20 from $16 but retained a Hold rating. Wells Fargo increased its target to $19 from $18 while keeping an Equal Weight rating, suggesting limited upside at recent trading levels.
• Neutral Sentiment: The earnings improvement is encouraging, but Bausch + Lomb still reported a negative net margin, so investors may continue to focus on profitability, cash flow and execution of the company’s growth plan.

About Bausch + Lomb

Bausch + Lomb Corporation (NYSE: BLCO) is a global eye-health company that develops, manufactures and markets products for vision care, ophthalmic pharmaceuticals and eye surgery. The company serves consumers, eye-care professionals, hospitals and surgical centers through a portfolio spanning contact lenses, contact-lens care products, prescription medicines, over-the-counter eye-care products and surgical equipment.

Its vision-care portfolio includes the Biotrue and INFUSE contact-lens brands, as well as solutions and other products used to clean and maintain contact lenses.